DMDimitar T. Marinov

Dimitar T. Marinov

*This is an algorithmically generated author record based on publicly available information.

Dimitar T. Marinov has a total of 73 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Efficacy of alectinib in advanced ALK-positive non-small cell lung cancer: Results from the Russian multicenter KARL-005 study

    by D. T. Marinov, D. V. Perunov, L. N. Nefedova, I. S. Polyakov, A. F. Nasretdinov, A. A. Izmailov, A. V. Sultanbaev, M. I. Andrievskikh, R. A. Zukov, I. L. Obraz, et al.

    Introduction. Tyrosine kinase inhibitors, specifically alectinib, have significantly improved the prognosis for patients with advanced ALK-positive non-small cell lung cancer (ALK+ aNSCLC). National multicenter real-world data are essential to validate these outcomes within a broader clinical population. Aim. To evaluate the clinical efficacy of first-line alectinib in patients with ALK+ aNSCLC within routine clinical practice in the Russian Federation. Materials and methods. This multicenter retrospective study included patients who initiated first-line alectinib between 2020 and 2022. Primary endpoints included progression-free survival (PFS) and overall survival (OS) in the first-line setting. Secondary objectives assessed the prevalence of comorbidities and alectinib efficacy across clinical subgroups. Results. Data from 153 patients across 12 centers were analyzed. The median age was 56.7 years (range: 25.0–82.9), and 59.5% were female. At baseline, 21% of patients had an ECOG PS ≥ 2, and 20.3% presented with CNS metastases. Alectinib was administered as first-line therapy in 79 patients (51.6%), while 74 patients received it following prior chemotherapy. With a median follow-up of 47.8 months, the median PFS was 53.6 months (95% CI: 37.2 – NR) in the first-line cohort and 55.6 months (95% CI: 31.9 – NR) in the post-chemotherapy cohort. In the first-line group, median OS was not reached (5-year OS: 63.2%). For the post-chemotherapy group, median OS was 66.5 months (95% CI: 48.2 – NR; 5-year OS: 51.2%). Comorbidities were prevalent, notably cardiovascular disease (64.1%) and metabolic disorders (21.6%). Conclusion. Alectinib efficacy in Russian routine practice is comparable to the results of the landmark ALEX trial. The high prevalence of comorbidities highlights the need for a comprehensive, individualized approach to therapy selection in this population.

  • Open Access

    Eating behavior in patients with breast cancer

    by Anastasia V Knyazeva, Galina A. Tkachenko, Olga A. Obukhova, Mariya S. Trifonova, Dimitr T. Marinov, Natalya Yu. Shagina, Ildar A. Kurmukov, Maria A. Pestereva, Князева Анастасия Вячеславовна

    BACKGROUND: Patients with breast cancer in remission tend to be overweight; however, the global literature has no data on eating disorders in this category of women. AIM: To identify any potential eating disorders and their association with personality traits and emotional condition of women who underwent radical treatment for breast cancer and do not show any disease progression. MATERIALS AND METHODS: Thirty-two women who completed breast cancer treatment and did not show any disease progression in one year were asked to fill in Eating Attitude Test (EAT-26) and Big Five personality test and were evaluated with the Hospital Anxiety and Depression Scale (HADS). Microsoft Excel and Statistica 10.0 were used for statistical data processing. The critical significance level was p 0.05. RESULTS: 81.3% of the patients were overweight. A serious eating disorder was found in one patient. In 15.6% of patients were was evidence of strained relationship food. A statistically significant association was established between Neuroticism and Depression ( r =0.362) and between Agreeableness and Level of anxiety ( r =0.37). No correlation was discovered for the probability of an eating disorder and “level of anxiety/depression.” CONCLUSION: Serious eating disorders seem to be uncharacteristic of patients with breast cancer who have completed the treatment. The following pairs of descriptors were found to be associated: Agreeableness/Anxiety and Neuroticism/Depression.


  • Open Access

    Is it necessary to diagnose and correct vitamin D deficiency in malignant neoplasms? Analytical review

    by Natalya Y. Shagina, Olga A. Obukhova, Dimitar T. Marinov, Maria S. Trifonova, V. E. Ponomarev

    BACKGROUND: Although the critical role of vitamin D in mineral homeostasis regulation is widely recognized, the global prevalence of vitamin D deficiency is exceedingly high. The substantial number of population-based studies that examine the correlation between the concentration of circulating vitamin D levels and the risk of developing cancer may be attributed to the growing interest of researchers in this vitamin as a suppressor of proliferating epithelial cells. However, the data collected are contradictory. AIM: To ascertain the necessity of diagnosing and rectifying vitamin D deficiency in cancer patients. MATERIALS AND METHODS: The keywords “vitamin D,” “vitamin D deficiency,” “cancer,” and “survival” were employed to identify publications in the e-Library, PubMed, and ScienceDirect databases from January 2014 to January 2024. Based on the data obtained, an analytical review of the literature was conducted. RESULTS: The global prevalence of vitamin D deficiency, including among cancer patients, is exceedingly high and does not vary by sex, age, or ethnicity. Decreased serum vitamin D levels are linked to an elevated incidence of colorectal cancer, breast cancer, melanoma, prostate, and pancreatic cancer. Addressing vitamin D deficiency helped mitigate the risk of developing breast cancer. Data on the effect of vitamin D deficiency and its correction on patient survival are inconsistent. CONCLUSION: Currently, there is no consensus regarding the impact of vitamin D supplementation on the incidence of diverse malignancies, as well as tumor-specific and overall survival. Additional research is required to address the necessity of diagnosing and correcting vitamin D deficiency.

  • Open Access

    Radiation Therapy in Complex Treatment of Patients with Pleural Mesothelioma

    by T. N. Borisova, S. I. Tkachev, S. M. Ivanov, S. B. Alieva, O. P. Trofimova, V. V. Glebovckaya, V. V. Breder, K. K. Laktionov, D. T. Marinov

    Лучевая терапия в комплексном лечении больных мезотелиомой плевры

  • Open Access

    Stereotactic hypofractive radiotherapy in the treatment of patients with lung cancer

    by T. N. Borisova, A. V. Nazarenko, K. K. Laktionov, S. I. Tkachev, S. B. Alieva, V. V. Breder, O. P. Trofimova, V. V. Glebovskaya, A. A. Fedorova, D. T. Marinov, et al.

    Introduction. Nowadays the stereotactic radiotherapy (SRT) of patients with clinical stage I-II lung cancer is the choice of the treatment modality for functionally inoperable patients. It shows safety and high efficiency in reaching the local control. Though there is a range of unsolved issues connected with the prediction of treatment efficiency and frequency of complications, an integration of new technologies in the planning and treatment process allows to widen the search of the predictive factors.Materials and methods. Since 2014, 42 patients (T1N0M0 – 16 patients, T2N0M0 – 26 patients) with clinical stage I-IIa lung cancer have underwent SRT. The majority of patients (38) have been recognized as functionally inoperable due to the concurrent broncho-pulmonary pathology, 4 conditionally operable patients have refused an operation. 11 patients had the primary multiple tumors in their anamneses, 3 patients had a сentral tumor. Used dose fractionation options were: 10 Gy х 5 fractions (n = 29) and 7 Gy х 8 fractions (n = 13) – BED = 100 Gy.Resuts. The median follow-up was 32 months (range 6–56 months). The 3-year local control was 94%. The isolated local recurrences were not registered. Overall 3-year survival rate was 74% (95% CI, 60–90) and a 3-year tumor-specific survival rate – 84% (95% CI, 71–98). During one-factor analysis a reliable influence on the prognosis of the fractionation regimen (р = 0,04) and, close to reliability, the initial SUVmax level influence (р = 0,07) were revealed. Grade 3 pulmonary toxicity was observed in 4 (9%) patients, one patient with a Central tumor died from pulmonary hemorrhage (grade 5 toxicity). Grade 3 chest pain was observed in 3 (7%) patients, two of them had a rib fracture.Conclusions. With modern approaches to SRT treatment planning and delivery there should be a search for additional treatment efficiency and toxicity predictors. The total dose delivery regimen and initial tumor SUVmax can be predictive efficiency factors, while the pulmonary tissue volume can be a predictive toxicity factor.